# Alphamab Oncology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alphamab-oncology

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.alphamabonc.com
- Total disclosed funding: $160M
- Latest round: Series B (May 28, 2019)
- Investors on record: 7

## About

Founded in 2015 and based in Jiangsu, China, Alphamab Oncology is a biopharmaceutical company that develops and manufactures treatments for cancer and other viral infections and diseases. It is headquartered in Suzhou and has branches in Shanghai and Beijing. The company's founder, Chairman, and CEO, Dr. Tim Xu, has a B.S. in Biochemistry from Nanjing University and a Ph.D. in Biophysics from the Chinese Academy of Sciences. He has over 20 years of experience in the development of innovative biologics and has served as Principal Investigator and Project Leader for Archemix, Serono, and Biogen.

The company's self-developed technology platform includes a bispecific antibody development platform, a hybrid antibody development platform, and a biomolecule production platform. It also develops large molecule drugs and tumor immunotherapy, covering KN015, KN035, KN025, KN019 and other products.

The company generates revenue by providing innovative oncology drugs and related services.

## Funding rounds

- Series B, May 28, 2019, $60M — PAG, Hudson Bay Capital, China Venture Capital, Advantech Capital
- Series A, Nov 16, 2018, $100M — OrbiMed Advisors, PAG, Janchor Partners, Heritage Provider Network, Advantech Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- PAG (https://capitalatlas.ai/funds/pag) — Series A, Series B
- Janchor Partners — Series A
- Heritage Provider Network — Series A
- Advantech Capital (https://capitalatlas.ai/funds/advantech-capital) — Series A, Series B
- Hudson Bay Capital — Series B
- China Venture Capital (https://capitalatlas.ai/funds/china-venture-capital) — Series B